Why patients are partners in research and its documents
Patients contribute knowledge of living with illness, treatment burdens and information needs that can change research priorities, trial design and communication. Partnership gives that experience a role in decisions as well as participation and readership.
Lived experience and research decisions
Patient and public involvement and engagement (PPIE) brings patients' priorities and lived experience into the design, conduct and reporting of research. “Nothing about us without us” expresses the demand to contribute to decisions rather than only receive them. Patients can refine research questions, identify meaningful endpoints, influence eligibility and benefit–risk assessments, explain how they use instruments and activities, and support assessment of patient-reported adverse events, outcomes and quality of life. They can also review material, contribute lay summaries and act as publication reviewers and co-authors.
Researchers and patients may interpret unmet needs differently: a focus on pathophysiology can overlook symptoms, everyday functioning and quality of life that matter to people living with the condition. Early input can help align endpoints and trial procedures with those needs. Patients' views of a meaningful benefit can also differ from sponsors' expectations, including greater willingness to accept particular risks in exchange for a treatment that matters to them.
Engagement can mean societal participation, scientific contribution or both, and the term has sometimes been used without a clear definition. The shift from people contributing only trial readouts to helping shape decisions gives engagement a scientific dimension, including the choice of more useful endpoints and quality-of-life measures. A December 2025 assessment treated improvement in trial outcomes through patient inclusion as part of the scientific case for engagement.
Participation burden, trust and relevance
Patients may be more willing to join and remain in inclusive, transparent trials that reflect their interests and interfere little with daily life. Lengthy, complex or unnecessarily invasive procedures can make trials unattractive, while absent or late patient input may increase recruitment and retention problems, costs and completion time. Involvement in design and dissemination may increase participants' sense of control, build trust and collaboration and broaden the findings' impact and application. These are potential benefits of involvement rather than guaranteed results.
A patient-speaker account in May 2024 argued that involving patients and physicians across preclinical development, phases 1–3 and post-marketing could shorten timelines and improve research questions or endpoints.
Community priorities and shared decisions
A December 2025 interpretation of WHO clinical-trial guidance called for disease priorities to arise more from patient-community engagement, because communities often understand which diseases matter locally better than industry does. The proposal was to combine community and industry perspectives. Community engagement at national and regional level also gives patients a voice in health-authority decisions about clinical-research funding.
WHO guidance discussed in October 2025 recognised potential participants' and communities' contributions to trial design, execution and interpretation; the same discussion treated patient involvement under ICH E8(R1) and E6(R3) as best practice to follow as far as possible. ICH's 2021 reflection paper identified opportunities for patient perspectives to improve drug development's quality, relevance, safety and efficiency and inform regulatory decisions, including possible future harmonised guidelines for industry and authorities.
Building patients' knowledge of healthcare systems can empower them and bring issues they value into bodies such as NICE, supporting individual decisions shared with clinicians.
Information and accountability
By 2019, greater recognition of patient-facing information was likely linked to patients' roles as trial participants, contributors to drug development and medicine users, together with increasingly vocal patients and advocacy groups seeking control of health decisions and tailored information. This was reflected in more company-led patient-centred initiatives and new patient-focused regulatory requirements.
Patient centricity means putting the patient first through open, sustained, respectful and compassionate engagement aimed at the best experience and outcome for the person and family. Its practical elements include access to needed medicines, transparent and unbiased information on diseases and treatments, support for informed decisions, respectful listening and responses to feedback, and convenient plain-language information.
Study participants want to know results even when findings do not match researchers' expectations, and patient organisations seek involvement from study design to disclosure. A continuous feedback relationship with researchers and companies, rather than selective disclosure, recognises patients as an audience for research communication. Failing to share results effectively marginalises participants and can discourage future participation.
Complementary expertise in communication
A patient living with type 1 diabetes for twenty-eight years, speaking in 2025 and disclosing paid-ambassador status, described patient expertise as complementary to writers' expertise. Patients can identify missing information and wording that is too vague, cold or clinical, while co-creation need not dilute the professional's work. The practical case is also that the intended users can explain how communication could better meet their needs. The partnership recognises people as more than a diagnosis or the device they use, with lived expertise that can help improve care.